3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
4
Uterine Cervical Dysplasia
2
Stomach Neoplasms
2
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Squamous Intraepithelial Lesions
1
Precancerous Conditions
1
Papillomavirus Infections
1
Neoplasms by Site
1
Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Atypical Squamous Cells of the Cervix
1
Anus Neoplasms
1
Interventions
Cisplatin
4
atezolizumab
3
Nivolumab
3
Carboplatin
3
pembrolizumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
abemaciclib
2
Vemurafenib
2
Radiosurgery
2
Pemetrexed
2
Mitomycin
2
Fulvestrant
2
Drug Therapy
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
ribociclib
1
repotrectinib
1
relatlimab
1
relacorilant
1
pertuzumab
1
palbociclib
1
olaparib
1
lutetium Lu 177 dotatate
1
exemestane
1
enzalutamide
1
enfortumab vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms by Site
×
Human Papillomavirus DNA Tests
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled